Living with Wilson A patient-led project

← Back to all answers

Can I get pregnant with Wilson disease?

Yes. With careful planning, well-controlled Wilson disease is fully compatible with pregnancy and a healthy baby. The main considerations are medication choice, dose adjustment, and continued monitoring throughout pregnancy.

The short answer is yes. Wilson disease is not a contraindication to pregnancy. With proper preparation and supervision, the great majority of women with well-controlled Wilson disease have healthy pregnancies and healthy babies.1

The single most dangerous thing a Wilson patient can do during pregnancy is stop her medication out of fear that it will harm the baby. Untreated or undertreated Wilson disease during pregnancy — particularly with rebounding copper — is far more dangerous than the medications themselves.2 3

Before conception

Start the conversation with your medical team early — ideally 6 to 12 months before you plan to conceive.4 That lead time matters because:

  • Your hepatologist and an obstetrician familiar with rare metabolic diseases need to agree on a plan before you are pregnant, not after.
  • Your disease should be well-controlled: stable liver enzymes, urinary copper in target range, no active neurological symptoms.
  • If a medication switch makes sense for your situation, it is easier to make that change and confirm stability before pregnancy begins.

Medication choices in pregnancy

All three mainstream Wilson disease treatments have been used in pregnancy, with different levels of evidence and caution.1 4 5

Drug Pregnancy use
Zinc Considered the safest option; usually first-line if disease is well-controlled and the patient is stable on zinc already3
Trientine Generally considered acceptable; some clinicians prefer a reduced dose in the third trimester4
D-penicillamine Usable but typically dose-reduced in the second and third trimesters; carries a historical concern about connective-tissue effects at high doses (see below)5 6

In practice, many women on chelation therapy transition to zinc only during pregnancy. Others continue at lower chelator doses. The right choice is individual and should be made with your treating team — not decided alone based on internet reading.

A note on penicillamine and connective tissue

Early case reports in the 1970s described connective-tissue abnormalities (cutis laxa) in newborns whose mothers had taken high-dose penicillamine during pregnancy — primarily women being treated for rheumatoid arthritis or cystinuria at doses higher than those used in Wilson disease.6 These reports established that dose matters. For Wilson disease patients, where the dose is lower and the benefit of continuing treatment is real, the current guidance from both AASLD and EASL is that penicillamine can be continued at a reduced dose rather than stopped.4 5

During pregnancy

  • Continue all medication unless your specialist explicitly advises otherwise.
  • Liver enzymes and urinary copper should be checked each trimester.
  • Routine prenatal care applies, with your obstetrician informed of your diagnosis.
  • Uncontrolled Wilson disease during pregnancy can cause miscarriage, liver deterioration, and fetal copper toxicity — risks far greater than those of the treatments.2 7

Delivery and postpartum

Most deliveries are uncomplicated.1 After delivery, medication dosing usually returns toward pre-pregnancy levels — copper can mobilize postpartum, so monitoring continues.

Breastfeeding is generally considered compatible with zinc, which is the preferred agent during this period.3 Chelators such as trientine and penicillamine pass into breast milk to some degree; the decision to breastfeed on chelation therapy should be made with your physician based on your individual clinical situation.4

Genetic counselling

Your children’s genetic risk depends on whether your partner carries an ATP7B mutation. In the general population:

  • Every child of a Wilson disease patient inherits one mutated copy from the affected parent — making them an obligate carrier.
  • If your partner is not a carrier (the most common situation), your child will be a healthy carrier and will not develop Wilson disease.
  • If your partner happens to carry a single ATP7B mutation — roughly a 1-in-90 chance in the general population — each pregnancy has a 1 in 4 chance of Wilson disease.8

Pre-conception genetic counselling lets you understand the actual probability for your specific situation, and in some cases your partner can be tested. This is a practical step, not a reason to avoid pregnancy.9


If you are weighing whether pregnancy is “safe” — for nearly all well-controlled Wilson patients the answer is yes. Please bring this question to your treating team and not to the internet alone.

This post is patient education, not medical advice. Every patient’s situation is different. Decisions about medication during pregnancy must be made with your hepatologist and obstetrician.

References


  1. Pfeiffenberger, Jan, Sandra Beinhardt, Daniel N. Gotthardt, Nicola Haag, Clarissa Freissmuth, Ulrike Reuner, Annika Gauss, and Wolfgang Stremmel. “Pregnancy in Wilson’s Disease: Management and Outcome.” Hepatology 67, no. 4 (2018): 1261–1269. https://doi.org/10.1002/hep.29490. 

  2. Brewer, George J., Virginia D. Johnson, Robert D. Dick, Peter Hedera, and John K. Fink. “Treatment of Wilson’s Disease with Zinc. XVII: Treatment during Pregnancy.” Hepatology 31, no. 2 (2000): 364–370. https://doi.org/10.1002/hep.510310216. 

  3. Rabiee, Atoosa, and James P.A. Hamilton. “Pregnancy in Wilson Disease.” Hepatology 67, no. 4 (2018): 1201–1203. https://doi.org/10.1002/hep.29619. 

  4. Schilsky, Michael L., Eve A. Roberts, Jacqueline M. Bronstein, Anil Dhawan, and James P. Hamilton. “A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance on Wilson Disease from the American Association for the Study of Liver Diseases.” Hepatology 82, no. 3 (2022): E41–E90. https://doi.org/10.1002/hep.32801. 

  5. European Association for Study of the Liver. “EASL Clinical Practice Guidelines: Wilson’s Disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. 

  6. Mjølnerød, O.K., S.A. Dommerud, K. Rasmussen, and S.T. Gjeruldsen. “Congenital Connective-Tissue Defect Probably Due to D-Penicillamine Treatment in Pregnancy.” The Lancet 297, no. 7701 (1971): 673–675. https://doi.org/10.1016/s0140-6736(71)92681-x. 

  7. Reuner, Ulrike, and Juergen Dinger. “Pregnancy and Wilson Disease: Management and Outcome of Mother and Newborns — Experiences of a Perinatal Centre.” Annals of Translational Medicine 7, S2 (2019): S56. https://doi.org/10.21037/atm.2019.04.40. 

  8. Czlonkowska, Anna, Tomasz Litwin, Piotr Dusek, Per Ferenci, Rajiv Bhatt, Chantal Caumont, and others. “Wilson Disease.” Nature Reviews Disease Primers 4, no. 1 (2018): article 22. https://doi.org/10.1038/s41572-018-0024-5. 

  9. Alkhouri, Naim, Regino P. Gonzalez-Peralta, and Valentina Medici. “Wilson Disease: A Summary of the Updated AASLD Practice Guidance.” Hepatology Communications 7, no. 6 (2023). https://doi.org/10.1097/hc9.0000000000000150. 

This is patient education, not medical advice. Always consult your own clinical team about decisions for your care.